Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. UroGen Pharma Ltd shares valued at $250,000 were sold by Schoenberg Mark on Nov 19 ’25. At $25.00 per share, Schoenberg Mark sold 10,000 shares. The insider’s holdings dropped to 139,025 shares worth approximately $2.72 million following the completion of this transaction.
Also, Schoenberg Mark purchased 10,000 shares, netting a total of over 250,005 in proceeds.
Before that, Degnan Chris had sold 2,203 shares from its account. In a trade valued at $37,121, the Chief Financial Officer traded UroGen Pharma Ltd shares for $16.85 each. Upon closing the transaction, the insider’s holdings decreased to 2,203 shares, worth approximately $44551.2.
As published in their initiating research note from Piper Sandler on August 19, 2025, UroGen Pharma Ltd [URGN] has been an Overweight and the price target has been revised to $36. Analysts at H.C. Wainwright upgraded the stock from ‘”a Neutral”‘ to ‘”a Buy”‘ outlook in a report released in mid June. As of May 22, 2025, H.C. Wainwright has decreased its “Buy” rating to a “Neutral” for URGN. Earlier on April 16, 2025, Scotiabank initiated its rating. Their recommendation was “a Sector outperform” for URGN stock.
Analyzing URGN Stock Performance
On last trading session, UroGen Pharma Ltd [NASDAQ: URGN] rose 4.27% to $19.54. The stock’s lowest price that day was $18.35, but it reached a high of $19.6425 in the same session. During the last five days, there has been a drop of approximately -16.74%. Over the course of the year, UroGen Pharma Ltd shares have jumped approximately 96.78%.
Support And Resistance Levels for UroGen Pharma Ltd (URGN)
RSI (Relative Strength Index) is 37.20 on the 14-day chart, showing neutral technical sentiment.
Is UroGen Pharma Ltd subject to short interest?
Stocks of UroGen Pharma Ltd saw a sharp rise in short interest on 2025-12-31 jumping by 1.59 million shares to 9.54 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 7.95 million shares. A jump of 16.68% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 11.5 of the overall float, the days-to-cover ratio (short ratio) jumped to 11.5.
Which companies own the most shares of UroGen Pharma Ltd (URGN)?
In terms of UroGen Pharma Ltd share price expectations, FactSet research, analysts set an average price target of 31 in the next 12 months, up nearly 65.42% from the previous closing price of $18.74. Analysts anticipate UroGen Pharma Ltd stock to reach 60 by 2026, with the lowest price target being 16. In spite of this, 7 analysts ranked UroGen Pharma Ltd stock as Buy at the end of 2026. On February 19, 2025, Ladenburg Thalmann assigned a price target of “a Buy” to the stock and resumed coverage with a $31.
